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Summary
Background Bedaquiline and clofazimine are important drugs in the treatment of drug-resistant tuberculosis and are 
commonly used across southern Africa, although drug susceptibility testing is not routinely performed. In this 
study, we did a genotypic and phenotypic analysis of drug-resistant Mycobacterium tuberculosis isolates from cohort 
studies in hospitals in KwaZulu-Natal, South Africa, to identify resistance-associated variants (RAVs) and assess the 
extent of clofazimine and bedaquiline cross-resistance. We also used a comprehensive dataset of whole-genome 
sequences to investigate the phylogenetic and geographical distribution of bedaquiline and clofazimine RAVs in 
southern Africa. 
Methods In this study, we included M tuberculosis isolates reported from the PRAXIS study of patients with drug-
resistant tuberculosis treated with bedaquiline (King Dinuzulu Hospital, Durban) and three other cohort studies of 
drug-resistant tuberculosis in other KwaZulu-Natal hospitals, and sequential isolates from six persistently culture-
positive patients with extensively drug-resistant tuberculosis at the KwaZulu-Natal provincial referral laboratory. 
Samples were collected between 2013 and 2019. Microbiological cultures were done as part of all parent studies. We 
sequenced whole genomes of included isolates and measured bedaquiline and clofazimine minimum inhibitory 
concentrations (MICs) for isolates identified as carrying any Rv0678 variant or previously published atpE, pepQ, and 
Rv1979c RAVs, which were the subject of the phenotypic study. We combined all whole-genome sequences of 
M tuberculosis obtained in this study with publicly available sequence data from other tuberculosis studies in southern 
Africa (defined as the countries of the Southern African Development Community), including isolates with Rv0678 
variants identified by screening public genomic databases. We used this extended dataset to reconstruct phylogenetic 
relationships across lineage 2 and 4 M tuberculosis isolates.
Findings We sequenced the whole genome of 648 isolates from 385 patients with drug-resistant tuberculosis recruited 
into cohort studies in KwaZulu-Natal, and 28 isolates from six patients from the KwaZulu-Natal referral laboratory. 
We identified 30 isolates with Rv0678 RAVs from 16 (4%) of 391 patients. We did not identify any atpE, pepQ, or 
Rv1979c RAVs. MICs were measured for 21 isolates with Rv0678 RAVs. MICs were above the critical concentration 
for bedaquiline resistance in nine (43%) of 21 isolates, in the intermediate category in nine (43%) isolates, and 
within the wild-type range in three (14%) isolates. Clofazimine MICs in genetically wild-type isolates ranged from 
0·12–0·5 μg/mL, and in isolates with RAVs from 0·25–4·0 μg/mL. Phylogenetic analysis of the extended dataset 
including M tuberculosis isolates from southern Africa resolved multiple emergences of Rv0678 variants in lineages 2 
and 4, documented two likely nosocomial transmission events, and identified the spread of a possibly bedaquiline 
and clofazimine cross-resistant clone in eSwatini. We also identified four patients with pepQ frameshift mutations 
that may confer resistance.
Interpretation Bedaquiline and clofazimine cross-resistance in southern Africa is emerging repeatedly, with evidence 
of onward transmission largely due to Rv0678 mutations in M tuberculosis. Roll-out of bedaquiline and clofazimine 
treatment in the setting of limited drug susceptibility testing could allow further spread of resistance. Designing 
strong regimens would help reduce the emergence of resistance. Drug susceptibility testing is required to identify 
where resistance does emerge.
Funding Wellcome Trust, National Institute of Allergy and Infectious Diseases and National Center for Advancing 
Translational Sciences of the National Institutes of Health.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Articles
e166 www.thelancet.com/microbe   Vol 1   August 2020
Introduction
Tuberculosis continues to exert one of the most substan­
tial burdens of infectious disease globally. In 2018, half a 
million people were diagnosed with tuberculosis resistant 
to first­line drugs,1 and the number of patients receiving 
treatment for drug­resistant tuberculosis is increasing by 
over 10% annually.1 Bedaquiline, the first new tuber­
culosis drug in over four decades, has substantially 
improved drug­resistant tuberculosis outcomes2 since it 
was licensed in 2012. WHO has classified bedaquiline 
as a group A drug (to be included in all drug­resis­
tant tuberculosis regimens),3 and it is central to many 
clinical trial regimens for drug­susceptible tuberculosis 
(SimpliciTB, registered with ClinicalTrials.gov, 
NCT03338621) and tuberculosis resistant to first­line 
drugs (STREAM2, registered with ClinicalTrials.gov, 
NCT02409290) and second­line drugs (ZeNix­TB, 
registered with ClinicalTrials.gov, NCT03086486). 
Clofazimine was developed for tubercu losis in the 1950s, 
but given its limited efficacy compared with rifampicin 
and isoniazid, it has been primarily used to treat leprosy. 
Clofazimine has been incorporated into WHO guidelines 
for drug­resistant tuberculosis since 2011,4 and is now 
classified as a group B drug.3
Bedaquiline and clofazimine both act by impairing 
metabolism of mycobacterial energy. Bedaquiline binds 
to F1F0­ATP synthase preventing proton translocation, 
while clofazimine acts as a substrate for type II NADH 
dehydrogenase, the entry point for electrons into the 
respiratory chain, leading to generation of reactive 
oxygen species. Bedaquiline resistance is conferred by 
target mutations in the atpE gene,5 as well as non­target 
mutations in Rv0678 (a negative repressor of the MmpL5 
efflux pump)6 and pepQ (a cytoplasmic peptidase).7 Both 
non­target mutations cause cross­resistance to clofazi­
mine. Clofazimine resistance can also result from 
mutations in Rv1979c, although the mechanism is 
unclear.8 Serial passage of Mycobacterium tuberculosis in 
vitro in the presence of clofazimine selects for 
development of Rv0678 variants conferring bedaquiline 
cross­resistance, suggesting that clinical clofazimine use 
could lead to bedaquiline resistance even without 
bedaquiline use.9 Identification of resistance is limited by 
uncertainties over critical concentrations to differentiate 
resistant and susceptible isolates. The bedaquiline 
minimum inhibitory concentration (MIC) above which 
isolates are deemed resistant was set at 0·25 μg/mL on 
7H11 agar, although some isolates with Rv0678 mutations 
have MICs at or below this concentration.10 Because of 
scarce data, the clofazimine critical concentration has not 
been established for 7H11 agar, but has been set at 
1 μg/mL in mycobacterial growth indicator tube culture.10
Bedaquiline clinical trials were first done in KwaZulu­
Natal, South Africa, in 2007, and the region became an 
early adopter with over 3000 patients with drug­resistant 
tuberculosis receiving bedaquiline between 2012 and 2018 
(Iqbal Master, King Dinuzulu Hospital, Durban, personal 
communication). Likewise, clofazimine has been available 
in South Africa since 2012. In a clinical report published 
in February, 2020, that investigated the clinical course and 
treatment outcomes in a cohort of patients with drug­
resistant tuberculosis who were due to start 
Research in context
Evidence before this study
Resistance to bedaquiline in clinical isolates of Mycobacterium 
tuberculosis is commonly reported to be caused by mutations 
in the Rv0678 gene, with most mutations also conferring 
cross-resistance to clofazimine. In February 2020, we 
published a clinical report of baseline and emergent 
bedaquiline resistance caused by Rv0678 mutations in 
patients with drug-resistant tuberculosis in KwaZulu-Natal, 
South Africa. However, it is also important to know if these 
mutations caused clofazimine cross-resistance. To establish 
pre-existing knowledge on the distribution of bedaquiline and 
clofazimine resistance in southern Africa, we searched PubMed 
and Google Scholar for articles reporting clinical data in 
English published since 2000, using the terms “bedaquiline 
resistance” and “clofazimine resistance” in combination with 
country names for the Southern African Development 
Community. We excluded studies that only reported in vitro 
work. We identified three cohort studies from eSwatini and 
South Africa reporting a total of 12 isolates with bedaquiline 
and clofazimine resistance-associated variants and one case 
report of acquired bedaquiline and clofazimine resistance from 
South Africa.
Added value of this study
We identified 16 patients from our own studies with Rv0678 
mutations (ten of whom were included in the previous clinical 
report) and report bedaquiline minimum inhibitory 
concentrations for novel Rv0678 mutations as well as the range 
of clofazimine minimum inhibitory concentrations on 7H11 agar. 
In an extended sequence dataset combining our newly generated 
whole-genome sequencing data with publicly available sequences 
from the region, we identified emergence of putative resistance 
events across southern Africa, two possible cases of nosocomial 
transmission, and spread of a resistant clone in eSwatini.
Implications of all the available evidence
Many different Rv0678 mutations can cause bedaquiline and 
clofazimine cross-resistance. Resistance mutations are emerging 
in multiple locations and there is evidence of spread of resistant 
strains. This finding is concerning, given the key role bedaquiline, 
in particular, has in current and future treatment regiments for 
drug-resistant tuberculosis. Accelerated access to comprehensive 
drug susceptibility testing in southern Africa and worldwide is 
urgently required to ensure effective treatment and prevent 
spread of resistance.
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bedaquiline­based therapy in KwaZulu­Natal, we found 
baseline and emergent Rv0678 resis tance­associated 
variants (RAVs).11 Among sequenced isolates, five (5%) of 
92 had baseline Rv0678 variants. Although none had 
bedaquiline MICs above the critical concentration, three 
of five had MICs at the top of the wild­type range and 
patients with baseline Rv0678 variants had worse 
outcomes than those without. Emergent Rv0678 variants 
occurred in five (6%) of 87 isolates and were all associated 
with bedaquiline MICs that were above the critical 
concentration and worse outcomes. No patient had been 
previously treated with bedaquiline or clofazimine.
Until early 2020, neither genotypic nor phenotypic 
drug susceptibility testing for bedaquiline and 
clofazimine had been routinely performed in KwaZulu­
Natal, although phenotypic drug susceptibility testing 
has now been implemented in South Africa. Reports 
describing the presence of bedaquiline and clofazimine 
resistance in southern Africa (defined as the countries of 
the Southern African Development Community) have 
been scarce.12,13 In this study, we present genotypic and 
phenotypic data for M tuberculosis isolates with RAVs 
identified from our clinical report11 and other 
unpublished (to date) cohort studies at the Africa Health 
Research Institute, and report a more extensive micro­
biological investigation of bedaquiline and clofazimine 
MICs to investigate the extent of cross­resistance. To 
better understand the phylogenetic and geographical 
distribution of bedaquiline and clofazimine RAVs in 
southern Africa, we then analysed a compre hensive 
collection of our own and publicly available whole­
genome sequencing data.
Methods
Study design and isolate selection
In the phenotypic analysis, we included all 
M tuberculosis isolates from patients with Rv0678 variants 
in the PRAXIS study (registered with ClinicalTrials.gov, 
NCT03162107)11 and in three other cohort studies of 
drug­resistant tuberculosis. We also included sequential 
isolates from one persistently culture­positive patient with 
extensively drug­resistant tuberculosis with Rv0678 
variants at the KwaZulu­Natal provin cial referral laboratory 
(table 1). Sputum samples for culturing were collected 
between 2013 and 2019, with most collected from 
2016 onwards. Microbiological cultures were done as part 
of all parent studies. Whole­genome sequencing and 
measure ments of bedaquiline and clofazimine MICs were 
done as part of this study. RAVs considered able to cause 
bedaquiline or clofazimine resistance (ie, any Rv0678 
variant and previously published atpE, pepQ, and Rv1979c 
RAVs; table 2) were identified from whole­genome 
sequences.
We also sequenced the whole genomes of isolates from 
an unpublished cohort of patients with drug­susceptible 
tuberculosis at our centre for inclusion in our phylogenetic 
analysis. All studies and use of provincial referral 
laboratory isolates (table 1) were approved by the 
University of KwaZulu­Natal Biomedical Research Ethics 
Committee.
Location Design Patients recruited Sputum collection 
time points
Number of 
patients
Number of 
isolates
PRAXIS (aim 1), 
NCT0316210711
King Dinuzulu 
Hospital, Durban
Observational 
cohort study
HIV co-infected, multidrug-
resistant or extensively 
drug-resistant tuberculosis 
starting bedaquiline
Baseline, month 1, 
month 2, month 3, 
month 4, month 5, 
month 6, end of 
treatment
76 145
PRAXIS (aim 2), 
NCT0403273011
King Dinuzulu 
Hospital, Durban
Randomised 
controlled trial 
HIV co-infected, multidrug-
resistant or extensively 
drug-resistant tuberculosis 
starting bedaquiline
Baseline, month 2, 
month 6, end of 
treatment
41 53
Hlabisa DR-TB, 
unpublished
Hlabisa Hospital, 
uMkhanyakude 
District
Observational 
cohort study
Multidrug-resistant 
tuberculosis
Baseline 113 113
CUBS (FIND arm), 
unpublished
King Dinuzulu 
Hospital, Durban
Observational 
cohort study
Multidrug-resistant 
tuberculosis
Baseline, month 2, 
month 6, end of 
treatment
64 81
CUBS (PZAP arm), 
unpublished
Don Mackenzie 
Hospital, Durban
Observational 
cohort study
Multidrug-resistant 
tuberculosis
Baseline, week 1, 
week 2, week 4, 
week 6, month 2, 
month 3, month 4, 
month 5, month 6, 
end of treatment
91 256
Provincial referral 
laboratory isolates
Inkosi Albert Luthuli 
Central Hospital, 
Durban
Ad hoc Extensively drug-resistant 
tuberculosis
NA 6 28
ClinicalTrials.gov study registration numbers of isolate sources have been added, if available. All isolates were collected in KwaZulu-Natal, South Africa. A total of 676 isolates 
were collected from 391 patients. NA=not applicable.
Table 1: List of isolate sources including four cohort studies, a randomised clinical trial, and a provincial referral laboratory
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In PRAXIS11 and three additional cohort studies (table 1), 
serial sputum samples were obtained at weekly or monthly 
intervals for mycobacterial growth indicator tube culture 
and solid culture on Middlebrook 7H11 agar. Provincial 
referral laboratory isolates were previously cultured in 
mycobacterial growth indicator tubes and were regrown 
in Middlebrook 7H9 media from glycerol stocks. Positive 
cultures from clinical studies underwent phenotypic drug 
susceptibility testing for first­line and second­line drugs 
(rifampicin, isoniazid, ethambutol, kanamycin, ofloxacin) 
on 7H11 agar by the 1% proportion method.
Bedaquiline and clofazimine MICs were measured for 
all isolates from our clinical studies (table 1) whose 
genome was identified to carry any Rv0678 variant or any 
of the previously published RAVs listed in table 2. When 
isolates with the same mutation were collected from the 
same patient at multiple timepoints, MICs were not 
measured for the isolates derived from samples collected 
at intermediate timepoints. MICs were measured on 
7H11 agar using the proportion method at the Africa 
Health Research Institute laboratory in Durban, South 
Africa. Isolates were first grown in 7H9 liquid media 
adjusted to an optical density at 590 nm of 0·16, from 
which 10­fold dilutions were prepared. Neat, 10–² and 
10–⁴ suspensions were inoculated onto 7H11 agar 
containing bedaquiline concentrations of 0·03 μg/mL, 
0·06 μg/mL, 0·12 μg/mL, 0·25 μg/mL, 0·5 μg/mL, 
1·0 μg/mL, 2·0 μg/mL, 4·0 μg/mL, and 8·0 μg/mL, and 
clofazimine concentrations of 0·06 μg/mL, 0·12 μg/mL, 
0·25 μg/mL, 0·5 μg/mL, 1·0 μg/mL, 2·0 μg/mL, and 
4·0 μg/mL. M tuberculosis strain H37Rv was included in 
each batch for quality control. All plates were incubated 
at 37°C and read at 4 and 6 weeks.
Whole-genome sequencing
DNA was extracted by mechanical ribolysis, which was 
performed five times at 7000 revolutions per minute for 
1 min each (with 1­min intervals on ice) before purification 
with AMPure XP beads (Beckman Coulter, Indianapolis, 
IN, USA).23 Genomic libraries were prepared with 
NEBNext Ultra II DNA (New England Biolabs, Ipswich, 
MA, USA) according to the manufacturer’s instructions, 
and seque nced on a NextSeq 500 (Illumina, San Diego, 
CA, USA) 300­cycle mid­output run, with 48 samples 
multiplexed. The whole­genome sequencing bio­
informatics pipeline is described in the appendix (p 3).
Phylogenetic analysis
For our analysis of the phylogenetic and geographical 
distribution of bedaquiline and clofazimine RAVs in 
southern Africa, we compiled datasets of lineage 2 
and lineage 4 M tuberculosis whole­genome sequences 
obtained from PRAXIS aims 1 and 2, three observational 
cohort studies, and six patients with persistently culture­
positive, extensively drug­resistant tuberculosis from the 
provincial referral laboratory (table 1). To retrieve further 
sequences with variants in Rv0678, we used BIGSI 
(version 0.3.8)24 to screen publicly available M tuberculosis 
sequences indexed by the National Center for 
Biotechnology Information (NCBI) Sequencing Read 
Archive from southern Africa against an internally 
developed updated index (to April, 2019) for previously 
reported Rv0678 RAVs and those we identified in this study 
(table 2). We also included publicly available sequences 
from previously published studies in southern Africa. 
Suitable studies from eSwatini, Malawi, and South Africa 
were identified as described in the appendix (p 3).25–30 
Sequences were classified by lineage using phylogenetic 
single­nucleotide polymorphisms (SNPs).31 Those con­
taining more than one sublineage­specific SNP were 
classified as mixed infections and excluded. For lineage 2, 
H37Rv (GenBank accession NC_000962.3) was included 
as an outgroup while a lineage 3 outgroup (NCBI 
Sequencing Read Archive accession SRR1188186) was 
included for lineage 4. A maximum­likelihood phylogeny 
was constructed on both sets of SNP alignments using 
RaxML­NG (version v0.9.0) with 100 bootstrap replicates, 
a GTR+G substi tution model, and performing 
ascertainment correction for the number of invariant 
sites. Resulting phylogenies were plotted using ggtree 
(version 1.16.5).
Classification of RAVs
Where MICs were not available for public sequence data, 
Rv0678 mutations were annotated as resistance­associated 
if they had previously been associated with a MIC above 
the critical concentration of 0·25 μg/mL in 7H9 or 7H11 
media. To account for the area of technical uncertainty 
covering strains with MICs equal to the critical concen­
tration of 0·25 μg/mL, we introduced an intermediate 
category which had previously been proposed to incor­
porate isolates with a MIC falling outside 95% of wild­
type strains.32 Strains were labelled susceptible if they 
were previously associated with a MIC in the wild­type 
Gene Variant
Bedaquiline atpE Asp28Ala,14 Asp28Gly,14 Asp28Asn,15,16 Asp28Pro,16 Asp28Val,9 
Leu59Val,16 Ala63Pro,16 Ala63Val,15 Ile66Met16
Clofazimine Rv1979c Val52Gly,17 Val351Ala8
Bedaquiline and 
clofazimine
Rv0678 Val1Ala (this study),18 Val1fs (this study), Val20Gly (this study),19 
Gln22Pro (this study), Cys46fs (this study),20 Asp47fs, Pro48fs,20 
Glu49fs (this study),20 Ala59Val,21 Ile67fs (this study), Arg90Cys,22 
Phe93Ser (this study), Arg94Gln,5 Asn98Asp,22 Arg109Leu (this 
study), Ala118Thr (this study), Gly121Arg (this study), Leu136Arg 
(this study), Met146Thr, 17 Glu147fs (this study), Arg156fs (this study) 
Bedaquiline and 
clofazimine
pepQ Ala14fs,7 Leu44Pro,7 Arg271fs,7 any frameshift variant
Rv0678 variants are listed if associated with intermediate or full resistance to bedaquiline or clofazimine, as reported in 
previous publications or found in this study (appendix p 7). Previously published resistance-associated variants (RAVs) 
and any mutation to Rv0678 were used to select clinical isolates for bedaquiline and clofazimine minimum-inhibitory 
concentration measurement. All RAVs in this table, including those identified in this study, were used to classify 
variants identified in our phylogenetic analysis. 
Table 2: Mycobacterium tuberculosis variants potentially associated with resistance to bedaquiline or 
clofazimine
See Online for appendix
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distribution, or unknown if MIC data were not previously 
reported. The promoter variant –11 C→A was classified as 
hypersusceptible.21 The references used for labelling 
bedaquiline­resistant strains with Rv0678 mutations are 
shown in the appendix (p 7). Variants in atpE, pepQ, and 
Rv1979c were considered as potentially causative of 
resistance if they were located at sites previously 
associated with resistance (table 2).
Statistical analysis
A correlation between bedaquiline and clofazimine MICs 
was calculated with Spearman’s correlation using Stata 
(version 15.1; StataCorp, TX, USA).
Role of the funding source
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all the 
data in the study and the corresponding author had final 
responsibility for the decision to submit for publication.
Results
We performed whole­genome sequencing on 648 isolates 
from 385 patients with drug­resistant tuberculosis 
recruited into cohort studies in KwaZulu­Natal, and 
28 isolates from six patients from the KwaZulu­Natal 
referral laboratory. We identified 30 isolates with Rv0678 
RAVs from 16 (4%) of 391 patients (appendix pp 8–9). 
RAVs from ten of these patients and associated 
bedaquiline MICs have been previously reported.11 We 
did not identify any atpE, pepQ, or Rv1979c variants 
previously associated with resistance. RAVs were present 
in pre­treatment samples in seven patients (five previously 
reported,11 two new) and emerged during treatment in 
eight patients (five previously reported,11 three new), with 
one patient unclassifiable because of the absence of a 
baseline sample. MICs were measured for 21 isolates 
with Rv0678 RAVs and seven isolates with wild­type 
Rv0678 (appendix pp 8–9). We did not measure MICs for 
seven isolates with RAVs as we had measured the MIC for 
a previous and subsequent sample from the same patient 
with the same mutations. Additionally, the MICs for the 
two samples from the provincial referral laboratory were 
not measured because of equipment unavailability at that 
location at that time.
Clofazimine MICs for isolates with wild­type Rv0678 
genes ranged from 0·12 to 0·5 μg/mL, while those with 
Rv0678 variants ranged from 0·25 to 4·0 μg/mL (table 3). 
MIC measurement failed for one isolate (P0121 with 
Phe93Leu RAV), giving MICs for a total of 20 isolates 
with Rv0678 RAVs. 
MICs were above the critical concentration for 
bedaquiline resistance in nine (43%) of 21 isolates 
(table 4; appendix pp 8–9), in the intermediate category 
in nine (43%) isolates, and within the wild­type range in 
three (14%) isolates. Isolate P0150 had an Glu49fs 
mutation at 72% allele frequency and MIC of 0·03 μg/mL 
that increased by month 2 to 97% allele frequency with 
MIC of 0·25 μg/mL in the absence of new mutations.11 
The same results were obtained on repeat testing. Isolate 
H0147 was phenotypically resistant when tested 
separately at a binary critical concentration of 0·25 μg/mL, 
but exhibited slow growth on MIC testing that might 
have led to a falsely low MIC, highlighting the challenges 
of MIC reproducibility near critical concentrations. 
Isolate P0121 had a fixed Phe93Leu mutation. 
Distributions of clofazimine and bedaquiline MICs in 
genetically wild­type and mutated isolates are shown in 
tables 3 and 4, indicating an area of technical uncertainty 
around 0·25–0·5 μg/mL for clofazimine and 0·25 μg/mL 
for bedaquiline. All clofazimine MICs that were below 
0·25 μg/mL occurred in genotypically wild­type isolates, 
and clofazimine MICs above 0·5 μg/mL all occurred in 
isolates with Rv0678 mutations. There was a correlation 
between bedaquiline and clofazimine MICs (R=0·81, 
p<0·0001; appendix p 4). Three separate variants were 
identified in Rv1979c (appendix pp 8–9): Glu38Asp, 
Asp286Gly and Arg409Gln. None of the variants in 
Rv1979c had been previously associated with resistance, 
and all were present in isolates with both low 
(<0·25 μg/mL) and high (>0·5 μg/mL) clofazimine 
MICs, suggesting that they were likely to be phylogenetic 
SNPs.
Of the 29 Rv0678 RAVs that were identified (between 
one and eight RAVs per patient), 24 (82%) were 
heteroresistant at the earliest time point. 23 different 
amino acid changes were iden tified, with only 
0·12 μg/mL 0·25 μg/mL 0·5 μg/mL 1·0 μg/mL 2·0 μg/mL 4·0 μg/mL
H37Rv 1 2 ·· ·· ·· ··
Clinical isolates
Wild type 2 4 1 ·· ·· ··
Val1Ala/Gly37fs/
Arg89Trp
.. .. 1 .·· ·· ··
Val20Gly ·· ·· ·· ·· ·· 1
Gln22Pro/Asp47fs ·· ·· ·· ·· 2* ··
Cys46fs ·· ·· ·· ·· 1 ··
Cys46fs/Asp47fs ·· ·· ·· ·· 2 ··
Asp47fs ·· ·· ·· ·· 2 ··
Asp47fs/Ile67fs/
Leu136Arg
·· ·· ·· ·· 1 ··
Glu49fs ·· 1 ·· ·· 1 ··
Ile67fs ·· ·· ·· ·· 1 1
Phe93Ser ·· ·· ·· 2 ·· ··
Arg109Leu/Arg156fs ·· ·· ·· 1 1 ··
Ala118Thr ·· ·· 1 ·· ·· ··
Glu147fs ·· ·· 1 ·· ·· ··
Mycobacterium tuberculosis strain H37Rv was included in each batch for quality control. WHO has not yet determined a 
critical concentration for clofazimine on 7H11 agar. MIC measurement failed for one (P0121, carrying the Phe93Leu RAV; 
appendix p 8, 19) of the 21 clinical isolates with Rv0678 variants we included in our analysis. MIC=minimum inhibitory 
concentration. *One isolate had an additional six Rv0678 mutations below 15% allele frequency. 
Table 3: Clofazimine MICs of 20 isolates tested on 7H11 agar with the 1% proportion method, showing 
number of isolates that have genetically wild-type Rv0678 and those with Rv0678 variants
Articles
e170 www.thelancet.com/microbe   Vol 1   August 2020
three occurring in more than one patient (Asp47fs in four 
patients, Ile67fs in three patients, and Cys46fs in 
two patients; appendix pp 8–9). One heterozygous variant 
increased in frequency to fixation (Arg96Gly in patient 
L001) while the others remained heterozygous, suggesting 
clonal interference with other heterozygous Rv0678 
variants in the same sample with coexistence of multiple 
separate genetic subpopulations.
Of the 16 patients with Rv0678 variants, eight (50%) 
were initially infected with lineage 4 M tuberculosis 
strains, seven (44%) with lineage 2 strains, and one (6%) 
with a lineage 1 strain. These proportions were broadly 
similar to the frequency of each lineage in our sequenced 
dataset of drug­resistant tuberculosis from KwaZulu­
Natal after excluding mixed infections: 2·8% (10/361) 
lineage 1, 35·5% (128/361) lineage 2, 1·9% (7/361) 
lineage 3, and 59·8% (216/361) lineage 4.
We did phylogenetic analyses of Rv0678 mutations in 
lineages 2 and 4—the two major M tuberculosis lineages 
present in South Africa and globally. The extended dataset 
of lineage 2 included 429 isolates (156 newly sequenced 
from our centre, including 33 from an unpublished drug­
susceptible cohort study) listed in the appendix (pp 10–17), 
and the extended dataset of lineage 4 included 698 isolates 
(247 newly sequenced from our centre, including 34 from 
an unpublished drug­susceptible cohort study) listed in 
the appendix (pp 18–30). In these extended datasets, we 
found an additional 39 patients with Rv0678 variants 
(five in lineage 2 and 34 in lineage 4), and an additional 
46 patients with lineage 2 infection who had the –11 C→A 
promoter mutation associated with low MICs to 
bedaquiline.21 We did not find any atpE, Rv1979c, or pepQ 
SNPs associated with resistance. However, we did find 
four patients in the extended dataset with strains carrying 
previously unreported pepQ frameshift mutations which 
might cause resistance in the extended dataset: two strains 
with Asp51fs mutations (at 97·8% and 16·1% allele 
frequen cies) in patients recruited into a study in Cape 
Town25 (NCBI Sequencing Read Archive accessions 
ERR1873424 and ERR1873561) that were genetically 
related (one SNP difference), one strain with Ile249fs 
(53·3% allele frequency) and Ser312fs (43·5% allele 
frequency) mutations (NCBI Sequencing Read Archive 
accession SRR1175307), and one patient with a Val273fs 
(12·1% allele frequency) mutation in combination with an 
Rv0678 G121R mutation (NCBI Sequencing Read Archive 
accession SRR1167167). All four strains were multidrug­
resistant or extensively drug­resistant tuberculosis as 
determined by whole­genome sequencing.
The phylogenetic relatedness of the isolates with Rv0678 
variants likely to be associated with resistance is shown in 
the figure and the appendix (pp 5–6). In the extended 
dataset of lineage 2 (our own plus publicly available data), 
Rv0678 RAVs were identified in 20 sequences from 
18 patients. Apart from three sequential samples from 
patient P0082 and the previously described possible 
nosocomial transmission to patient P0101 at King 
Dinuzulu Hospital (figure),11 the isolates from the other 
16 patients contained eight different mutations and were 
distributed throughout the phylogeny, indicating multiple 
independent emergence events. Five patients were from 
cohort studies at the Africa Health Research Institute, 
two were from a study in KwaZulu­Natal,26 and three from 
studies in Western Cape.25,27
Among the lineage 4 strains, we identified a clade of 
20 isolates from patients in eSwatini with a Met146Thr 
mutation,33 although both resistant and susceptible 
bedaquiline MICs have previously been reported with 
this variant.17,22 Overall Rv0678 variants were identified in 
49 isolates from 40 patients in the extended lineage 4 
dataset, of which six sequences from separate patients 
were identified from a previous study in KwaZulu­Natal.26 
Genetically identical sequences were isolated from three 
patients in Manguzi Hospital in KwaZulu­Natal within 
one month of each other (NCBI Sequencing Read Archive 
accessions SRR1184367, SRR1184369, and SRR1180407) 
that shared a Val1fs mutation, while the other samples all 
appeared to represent independent resistance emergence 
events.
Discussion
We identified a wide diversity of Rv0678 mutations in 
the genomes of clinical isolates from hospitals in 
KwaZulu­Natal that we sequenced and of publicly 
available strains in southern Africa, many of which have 
<0·03 
μg/mL
0·03 
μg/mL
0·06 
μg/mL
0·12 
μg/mL
0·25 
μg/mL
0·5 
μg/mL
1·0 
μg/mL
H37Rv ·· 1 2 ·· ·· ·· ··
Clinical isolates
Wild type 2 2 3 ·· ·· ·· ··
Val1Ala/Gly37fs/
Arg89Trp
·· ·· ·· ·· 1 ·· ··
Val20Gly ·· ·· ·· ·· 1 ·· ··
Gln22Pro/Asp47fs ·· ·· ·· ·· ·· 1* 1
Cys46fs ·· ·· ·· ·· ·· ·· 1
Cys46fs/Asp47fs ·· ·· ·· ·· ·· ·· 2
Asp47fs ·· ·· ·· ·· ·· 2 ··
Asp47fs/Ile67fs/
Leu136Arg
·· ·· ·· ·· ·· ·· 1
Glu49fs ·· 1 ·· ·· 1 ·· ··
Ile67fs ·· ·· ·· ·· 1 1 ··
Phe93Leu ·· ·· ·· 1 ·· ·· ··
Phe93Ser ·· ·· ·· ·· 2 ·· ··
Arg109Leu/
Arg156fs
·· ·· ·· ·· 2 ·· ··
Ala118Thr ·· ·· ·· 1 ·· ·· ··
Glu147fs ·· ·· ·· ·· 1 ·· ··
Mycobacterium tuberculosis strain H37Rv was included in each batch for quality control. *This isolate had an additional 
six Rv0678 mutations below 15% allele frequency.
Table 4: Bedaquiline minimum inhibitory concentrations of 21 isolates tested on 7H11 agar with the 
1% proportion method, showing number of isolates that have genetically wild-type Rv0678 and those 
with Rv0678 variants
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Figure: Phylogeny of southern African lineage 2 (A) and lineage 4 (B) Mycobacterium tuberculosis strains showing bedaquiline resistance profiles
Where multiple isolates originate from the same patient, this is indicated with a black line and the number of isolates. *Indicates likely nosocomial transmission (see 
main text).
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not been reported previously. This finding probably 
reflects the fact that Rv0678 is non­essential, and since 
the underlying resistance mechanism causing 
bedaquiline and clofazimine cross­resistance is loss of 
function (similar to pyrazinamide resistance caused by 
pncA mutations), there are potentially a large number of 
resistance­conferring variants. Most mutations with an 
associated MIC were likely to cause intermediate or full 
bedaquiline resistance. Initial reports of bedaquiline 
MICs in patients with Rv0678 mutations suggested a 
roughly even split of susceptible, intermediate, and 
resistant MICs,5 whereas here the majority of mutations 
seemed to have potential clinical significance. In our 
previous study,11 we identified worse clinical outcomes 
among the five patients with baseline Rv0678 variants 
even though MICs were susceptible or intermediate.11 
Furthermore, the range of different mutations we report 
in this study, spanning the length of the Rv0678 gene, 
means that development of a rapid molecular diagnostic 
could be challenging (as has been the case for 
pyrazinamide) and targeted or whole­genome sequencing 
is likely to provide the best solution to identify Rv0678 
RAVs.
We did not identify any previously reported atpE RAVs, 
which have been infrequently identified in clinical 
samples. atpE mutations have been previously found in 
vitro, but might have too high a fitness cost to occur 
frequently in clinical samples. Although we did not find 
any pepQ mutations in our own dataset, we did identify 
in publicly available data four strains with pepQ frame­
shift mutations that could confer resistance. However, 
while two previously reported pepQ frameshift variants 
conferred resistance,7 this has not been tested for other 
variants and therefore these findings should be inter­
preted with caution. Nevertheless, presence of these 
mutations suggests that it will be important to implement 
ongoing monitoring for pepQ variants with phenotypic 
testing.
We did not find evidence of Rv1979c mutations causing 
clofazimine resistance, with the mutations that we 
identified most likely to be phylogenetic variants. In the 
extended dataset, we found no previously reported Rv1979c 
variants associated with resistance, but this search is likely 
limited by the small number of reported mutations with 
correlated phenotypic data. Further work is needed to 
discern a critical concentration for clofazimine on 7H11 
agar, although our data suggest that both wild­type and 
mutant MICs cluster around the proposed critical 
concentration, challenging the establishment of a single 
meaningful cut­off, as is the case for bedaquiline.
Most Rv0678 variants were heterozygous and did not 
reach fixation. Four patients had M tuberculosis containing 
more than one heterozygous variant coexisting simul­
taneously. This points to multiple emergences of 
resistance within each patient, which was most extreme 
for one patient in particular who had eight different 
heterozygous variants by month 6. Heteroresistance 
has been identified with other tuberculosis drugs 
(although less frequently) and is most common for 
fluoroquinolones, where approximately 20% of resistance 
could be conferred by heterozygous RAVs.34 Importantly, 
heteroresistance might confound MIC testing if drug­
susceptible populations predominate in the phenotypic 
drug­susceptibility testing media, hiding the true 
dynamics of M tuberculosis in the host. An example from 
this study is isolate P0150, where the Glu49fs mutation 
(which has previously been associated with bedaquiline 
resistance)20,32 was present at 72% allele frequency at 
baseline with a bedaquiline MIC of 0·03 μg/mL, and 
increased by month 2 to 97% allele frequency with an 
MIC of 0·25 μg/mL in the absence of new mutations.11
The phylogenies we constructed for the two major 
epidemic M tuberculosis lineages in southern Africa 
(lineages 2 and 4) show RAVs across both lineages and in 
genetically distant strains, indicating multiple resistance 
emergence events. We additionally identified strains from 
earlier studies in KwaZulu­Natal carrying previously 
unidentified bedaquiline resistance. Worry ingly, in 
addition to the possible nosocomial transmission events 
at King Dinuzulu Hospital11 and Manguzi Hospitals (three 
patients sharing a strain with the Val1fs mutation), there 
is evidence of spread of a clone (genetically similar strains 
from different patients) carrying the Mer146Thr mutation 
in eSwatini which might confer raised bedaquiline MICs 
and requires further characterisation.17,22
These isolates were cultured from samples collected 
between 2009 and 2012, before the introduction of 
bedaquiline or clofazimine to eSwatini’s national 
tuberculosis programme, suggesting that the mutation 
was selected for by another evolutionary pressure. For 
example, it could have originated in a patient treated 
with clofazimine for leprosy or an azole for fungal 
disease who was co­infected with M tuberculosis, with the 
azole for fungal disease a more likely possibility given 
the low incidence of leprosy in eSwatini and the high 
incidence of HIV and potential for opportunistic fungal 
infections.6,35,36 Given that bedaquiline and clofazimine 
have both been used in eSwatini since 2014–15, urgent 
action is required to ensure that unidentified bedaquiline 
and clofazimine resistance does not spread in a similar 
fashion to that of rifampicin resistance conferred by the 
rpoB Ile491Phe mutation and missed by Xpert MTB/
RIF.33 The significance, if any, of the –11 C→A promoter 
mutation remains uncertain. Given its phylogenetic 
restriction to one clade of lineage 2, it might represent a 
chance mutation or adaptation to an as yet unidentified 
pressure.
One limitation of this study is that we only measured 
bedaquiline and clofazimine MICs on isolates from our 
centre with RAVs, because of the time and cost 
constraints. The resistance mechanisms mediated by 
Rv1979c and pepQ remain largely unexplained, so we will 
have missed unreported RAVs in these genes and in 
other, as yet unidentified genes. In the extended 
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phylogenetic dataset we used a comprehensive approach 
to identify all Rv0678 RAVs, but were unable to use this 
approach for other resistance­associated genes because 
of the greater presence of phylogenetic SNPs and lack of 
phenotypic correlation in other genes. We will therefore 
not have identified resistance conferred by as yet 
unidentified mechanisms. Previously reported resistance 
associated with Rv0678 variants was based on published 
reports and our own data, but for many RAVs only small 
numbers of reports exist, making it chal lenging to 
establish a robust causative relationship. Both data from 
our centre and publicly uploaded datasets are incomplete 
and likely to both miss resistance that is present and 
under­represent the large number of fully drug­
susceptible strains circulating. Among publicly uploaded 
data, we aimed to exclude duplicate samples by ensuring 
samples had unique BioSample identifiers and patient 
identification numbers. However, it is not possible to 
completely exclude that some isolates were sequenced 
more than once and uploaded with different identifiers.
Our data suggest that bedaquiline and clofazimine cross­
resistance mediated by Rv0678 mutations is emerging 
throughout southern Africa. The rollout of bedaquiline 
and clofazimine treatment, in the setting of limited drug­
susceptibility testing and inadequate adherence support, 
could allow the spread of emergent resistance. Designing 
strong regimens to be used programmatically such as 
those currently in use in South Africa, which include 
highly effective drugs such as linezolid, might help reduce 
emergence of resistance. Additionally, drug susceptibility 
testing is required to identify regions where resistance 
does emerge, which could involve a combination of 
genotypic and phenotypic methods.
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